As An Enabler of Personalized Therapeutics, Companion Diagnostics Witnesses Unprecedented Development & Commercialization Efforts

Growing role of personalized medicine and theranostics in disease treatment is poised to drive the global market for Companion Diagnostics to reach US$5.8 billion by 2022. A Companion Diagnostic (CDx) refers to a diagnostic test used as a companion to a therapeutic drug for increased efficacy of the drug and for pre-determining the efficacy of the treatment. CDx are usually in-vitro devices or assays or imaging tools, which are developed during development of the corresponding drug or after the drug is on the market. By providing crucial information on an individual’s risk factors for hard-to-diagnose conditions, and also predicting safety and efficacy of the drug in relevance to the targeted patient group, companion diagnostics enable healthcare professionals to decide whether a drug’s benefits outweigh its risks. They help doctors in appropriate dosage of medication, determine how well a patient is responding to a prescribed therapy, and also analyze risk of recurrence of a disease. Use of CDx during drug development and clinical trials increases the success rate of drugs, because they can identify patient sub-groups that are most likely to respond to a certain treatment and thus guide therapy decisions and improve patient outcomes, in turn reducing healthcare expenditure.

Companion diagnostics have ushered the emergence of personalized medicine, a breakthrough approach in the clinical treatment process. Companion diagnostics evaluate the safety and efficacy of a drug as well as optimum dosage for treating a patient, thereby paving the way for the practice of personalized medicine. Collaborations and partnerships between pharmaceutical companies and diagnostic technology providers are resulting in simultaneous approval of drugs and their corresponding companion diagnostics. In terms of technology, Next-Generation Sequencing (NGS) is expected to boost the CDx market, on account of its capability to identify multiple genes simultaneously and yield superior results. Oncology represents the leading application area for companion diagnostic development, with most of the FDA-approved companion diagnostics developed for breast cancer, lung cancer, gastric cancer, colorectal cancer, and melanoma. Breast cancer, especially, has been the highest revenue grosser, because most CDx were developed to detect the HER/neu biomarker for breast cancer. Neurology represents a therapeutic area with rapid growth potential, owing to unmet medical needs and extensive R&D in therapies for Alzheimer’s and Parkinson’s disease.

As stated by the new market research report on Companion Diagnostics, the United States represents the largest market worldwide. Asia-Pacific ranks as the fastest growing market, with a CAGR of 17% over the analysis period. The growth in the region is led by growing population, prevalence of diseases, increased spending on healthcare R&D by governments, migration to value based healthcare and higher per capita healthcare spending by the growing base of affluent middle class population.

Major players in the market include Abbott Molecular, Agilent Technologies Inc., bioMérieux SA, Cepheid, Danaher Corporation, F. Hoffmann-La Roche Ltd., Foundation Medicine Inc., Laboratory Corporation of America® Holdings, Leica Biosystems Nussloch GmbH, Merck & Co. Inc., Myriad Genetics Inc., NeoGenomics Inc., QIAGEN N.V., Quest Diagnostics Inc., and Thermo Fisher Scientific Inc., among others.

The research report titled "Companion Diagnostics - Market Analysis, Trends, and Forecasts" announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, growth drivers, mergers and acquisitions, and other strategic industry activities of major companies worldwide. The report provides market estimates and projections for geographic markets, such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia-Pacific (China and Rest of Asia-Pacific), Latin America, and Rest of World. Application areas analyzed for the global market include Oncology, Neurology, and Others (including Cardiovascular and Gastrointestinal therapy areas).  

For enquiries e-mail us at rsd@strategyr.com or info411@strategyr.com.

For cutting edge analyst reviews on top industries
Follow us on Twitter; Connect with us on LinkedIn; Follow us on Medium

Comments

Post a Comment

Popular posts from this blog

The Global Market for Big Data Technologies and Services is Projected to Reach $60 Billion by 2022

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Big Data market. The global market for Big Data Technologies and Services is projected to reach $60 billion by 2022 , driven by soaring digital data volumes in organizations and the resulting need to turn this data into valuable insights for enhancing operational efficiency, tapping new opportunities and gaining competitive edge. Defined as a natural result of mankind’s obsession with information technology and digitalization, “Big Data” refers to extremely large sets of structured, semi-structured and unstructured data of different types, including text, audio or video, generated from diverse data sources that has the potential to be mined for required information. While data supply associated with big data ecosystem has always been large and voluminous in most organizations, the ability to use these large datasets and convert them into meaningf
Read more

The Global Market for Surfing is Projected to Reach US$9.5 Billion by 2022

Rise of Surfing as a Lifestyle Sport Among all Age Groups Drives the Global Surfing Market, According to a New Report by Global Industry Analysts, Inc. GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Surfing market. The global market for Surfing is projected to reach US$9.5 billion by 2022 , driven by the growing interest in surfing both as a leisure and sporting activity, increased accessibility to surfing through surf parks and surf pools and technology innovations focused on developing sophisticated surf-wear and surf-gear.                               Surfing is a surface water sport where a participant riding a board (the surfboard) is carried away by a breaking wave. The surfing industry continues to evolve, driven by sustained efforts of surfing equipment makers, marketers and associations to make surfing much more accessible. Increased accessibility and affordability has drawn si
Read more

The Global Market for Private Tutoring Services is Forecast to Reach US$227 Billion by 2022

Intense Competition among Students and the Growing Need to Achieve Academic Excellence Drive the Global Private Tutoring Market, According to a New Report by Global Industry Analysts, Inc. GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Private Tutoring market. The global market for Private Tutoring Services is forecast to reach US$227 billion by 2022 , driven by the need to keep pace with classroom teaching, improve overall competency and enhance knowledge and skill level. Education is considered the social ladder to achieve success in personal and professional life. Higher education is associated with increased opportunities in the labor market, high remunerations, and improved social standing. People are therefore investing heavily in children’s education, including private tutoring or private supplementary tutoring which is emerging as a major phenomenon in the global education system
Read more